Bristol Myers Squibb: A Cash-Generating Machine at a Cheap Price

With the market at an all-time high, an investor would be hard-pressed to find a stock trading at an earnings multiple that's less than its growth rate while sporting a dividend yield close to 3%. But Bristol Myers Squibb (NYSE: BMY) is such a stock. With its recent acquisition of Celgene, Bristol is in the process of creating a cash-generating machine that should merit a higher valuation and reverse its underperformance in 2019.